(Total Views: 408)
Posted On: 12/10/2018 10:24:02 PM
Post# of 72446
IPIX...BRING ON THE BRILACIDIN OM & UP EMPIRE BECAUSE ALL OF THE BIG BIO-PHARMA ARE FAILING TO BRING WHAT IPIX ALREADY HAS PROVED THRU PHASE II TRIALS AND IPIX NEEDS TO BE HEARD AND WIDE EYES OPEN WITH THERE FDA MEETING :
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer Dec 7, 2018
AstraZeneca is still stinging from Imfinzi’s combo flop in non-small cell lung cancer, but it’s already staring down another defeat.
On Friday, the British drugmaker said the immuno-oncology drug had failed to show it could extend the lives of patients with recurrent or metastatic head and neck cancer whose disease has worsened after chemo.
The company tested both solo Imfinzi and a combination of Imfinzi and candidate tremelimumab in patients regardless of their expression levels of biomarker PD-L1, and neither option could top standard-of-care chemo. While the pharma giant will wait for an upcoming medical meeting to share full details of the miss, Sean Bohen, AZ’s chief medical officer, called the results “disappointing” in a statement.
Big money being wasted time ans time again by Big bio-pharma and IPIX sits with a blockbuster trifecta of a pipline .....the world and society have gone mad imho,tryz
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer Dec 7, 2018
AstraZeneca is still stinging from Imfinzi’s combo flop in non-small cell lung cancer, but it’s already staring down another defeat.
On Friday, the British drugmaker said the immuno-oncology drug had failed to show it could extend the lives of patients with recurrent or metastatic head and neck cancer whose disease has worsened after chemo.
The company tested both solo Imfinzi and a combination of Imfinzi and candidate tremelimumab in patients regardless of their expression levels of biomarker PD-L1, and neither option could top standard-of-care chemo. While the pharma giant will wait for an upcoming medical meeting to share full details of the miss, Sean Bohen, AZ’s chief medical officer, called the results “disappointing” in a statement.
Big money being wasted time ans time again by Big bio-pharma and IPIX sits with a blockbuster trifecta of a pipline .....the world and society have gone mad imho,tryz
(3)
(0)
